Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MILLNER, T.
Right arrow Articles by HURST, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MILLNER, T.
Right arrow Articles by HURST, A.
(Chest. 1949;16:870-878.)
© 1949 American College of Chest Physicians

Tuberculosis and Antihistaminics

TOVY MILLNER M.D.1 and ALLAN HURST M.D., F.C.C.P.1

1 The National Jewish Hospital, Denver, Colorado and the University of Colorado Medical Center, Denver, Colorado.

1) The present knowledge of antihistaminics, particularly the pharmacologic considerations are presented.

2) Tuberculous allergy and tuberculous anaphylaxis are presented as widely different mechanisms and carefully differentiated.

3) Neo-Antergan and phenergan ( RP3277) were given for several months in a series of thirty patients with tuberculosis. Although small changes in symptoms with slight improvement were noted in some cases, no definitive x-ray changes could be attributed to the use of these antihistaminics.

4) A further study using mainly cases with exudative lesions is planned.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1949 by the American College of Chest Physicians.